Atreca, a US-based immune-focused medicine developer based on research at Stanford University, completed an oversubscribed $125m series C round today led by an undisclosed existing investor described as a healthcare-focused fund.
The round included Tavistock Group’s Boxer Capital unit, Wellington Management Company, Cormorant Asset Management, Aisling Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.
Atreca is developing drugs based on the responsiveness of the human body’s immune system. Its lead program is…